Receptor News and Research

RSS

Discovery could provide new approaches to treat metabolic disorders

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic activator of a pair of proteins that belong to a protein family playing key roles in human metabolism and immune function. The discovery could provide new and potentially more effective therapeutic approaches to diseases ranging from diabetes to osteoporosis.

20 Nov 2010

Glenn Foundation awards $60,000 grant to Scripps' scientist for biomedical research

While scientists depend on grants for their research, applying for them is a long and frequently frustrating process. For one Scripps Research Institute scientist, however, the process was shorter.

19 Nov 2010

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.

19 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

New University of Georgia research, published this week in the early online edition of the journal Proceedings of the National Academy of Sciences, has found that blocking the action of an enzyme called GnT-V significantly delays the onset and spread of tumors in mice with cancer very similar to many cases of human breast cancer.

19 Nov 2010

GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events

Accumetrics, Inc., developer and marketer of the VerifyNow System, today announced that the GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) Trial found that in patients with high residual platelet reactivity, doubling the maintenance dose of clopidogrel did not reduce the risk of further ischemic events after percutaneous coronary intervention (PCI).

19 Nov 2010

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation.

19 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Cardiac stem cells from sick patients could generate new heart muscle: Research

Cardiac stem cells even in elderly and sick patients could generate new heart muscle and vessel tissue and be used to treat heart failure, according to research presented at the American Heart Association's Scientific Sessions 2010.

18 Nov 2010

Researchers reveal mechanism of early-stage anthrax infection

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined a key mechanism by which Bacillus anthracis bacteria initiate anthrax infection despite being greatly outnumbered by immune system scavenger cells. The finding, made by studying genetically modified mice, adds new detail to the picture of early-stage anthrax infection and supports efforts to develop vaccines and drugs that would block this part of the cycle.

18 Nov 2010

miR765 RNA may play a role in development of heart failure: Research

Researchers at the University of Cincinnati (UC) have found a potential genetic target for heart disease, which could lead to therapies to prevent the development of the nation's No. 1 killer in its initial stages.

18 Nov 2010

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

Idera Pharmaceuticals, Inc. announced today that it is presenting preclinical data from a study evaluating the mechanism of action of one of its Toll-like receptor (TLR) 7 and TLR9 antagonist candidates in a model of hyperlipidemia.

18 Nov 2010

Scientists investigate new class of drugs for treating kidney failure

Scientists are learning more about how protein gets in the urine when the kidneys begin to fail and how a new drug blocks it.

17 Nov 2010

Scientists determine ways to stop damage, promote neuronal growth in spinal cord injury

If researchers could determine how to send signals to cells responding to a spinal cord injury, they might be able to stop one type of cell from doing additional damage at the injury site and instead, coax it into helping nerve cells grow.

17 Nov 2010

New animal research identifies factors that may play key roles in depression

New animal research has identified factors, such as the stress response and immune system, that may play important roles in depression. Scientists have also found that the regulation of nerve cell signals influences depression in animals, and that new drug combinations may more effectively treat it. The findings were presented at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

Receptor News and Research

Discovery could provide new approaches to treat metabolic disorders

Glenn Foundation awards $60,000 grant to Scripps' scientist for biomedical research

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

ACE-041 drug may provide new option to treat cancer

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

Scientists solve receptor structure that responds to neurotransmitter dopamine

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Cardiac stem cells from sick patients could generate new heart muscle: Research

Researchers reveal mechanism of early-stage anthrax infection

miR765 RNA may play a role in development of heart failure: Research

Idera presents data on TLR7, TLR9 antagonist candidate for hyperlipidemia at American Heart Association

Scientists investigate new class of drugs for treating kidney failure

Scientists determine ways to stop damage, promote neuronal growth in spinal cord injury

New animal research identifies factors that may play key roles in depression

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Study: EGFR inhibtion may help treat triple negative breast cancer

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News